ArticleJournal of experimental & clinical cancer research : CR2026
Disruption of HSPA8-GEMIN5 interaction suppresses colorectal cancer by impaired splicing-translation coupling-mediated proteostasis imbalance.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Label-Free Target Discovery Strategy for Natural Active Products.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is one of the most prevalent malignant tumors globally, and there is an urgent need for effective treatment strategies. The natural compound Deoxyshikonin (DSHK) has shown promising anti-tumor potential. However, the anti-CRC effects of DSHK and its molecular target remain unclear.
methodsThe anti-CRC efficacy of DSHK was evaluated using human CRC cell lines, patient-derived organoids (PDOs), cell line-derived xenograft (CDX), and patient-derived organoid xenograft (PDOX) models. Target identification involved chemical proteomics, CETSA, SPR, and molecular dynamics simulations. Protein interactions were probed using SPIDER proximity labeling, Co-IP, GST pull-down, and confocal microscopy. The spatial distribution of interacting proteins was examined through high-density tissue microarrays, and functional pathways were explored via whole-transcriptome sequencing, rMATS, and ultrastructural imaging.
resultsDSHK demonstrated potent antitumor efficacy in preclinical models of CRC. HSPA8 was identified as the direct molecular target of DSHK. Moreover, the anti-CRC effect of DSHK depended on HSPA8. Additionally, GEMIN5 was identified as a novel functional interactor of HSPA8 in CRC pathogenesis. The expression levels and co-localization intensity of HSPA8 and GEMIN5 were significantly higher in CRC tissues compared to adjacent normal tissues. Moreover, DSHK destabilized the oncogenic HSPA8-GEMIN5 complex, thereby triggering aberrant splicing of ribosomal protein-coding genes mediated by GEMIN5, thereby impeding functional ribosome biogenesis. Concomitantly, DSHK impaired HSPA8-mediated initiation factors interaction and destabilized the eIF4F complex, resulting in dysfunctional translation initiation.
conclusionsDSHK targeted the HSPA8-GEMIN5 interaction interface to impair ribosome biogenesis and dysregulating translation initiation to suppress protein synthesis. This study established the newly identified HSPA8-GEMIN5 complex as a molecular hub mediating “splicing-translation coupling” in CRC and provided a novel “dual-pathway intervention targeting splicing and translation” strategy inducing proteostasis imbalance for CRC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.